Table 3: Accumulative adverse events during the 52 weeks of treatment.

Adverse eventTreatment group
(n = 136)
Control group
(n = 135)
value

Fatigue28 (20.6)25 (18.5)0.760
Upper abdominal pain21 (15.4)19 (14.1)0.864
Diarrhea24 (17.6)22 (16.3)0.872
Nausea21 (15.4)22 (16.3)0.869
Dyspepsia33 (24.3)35 (25.9)0.781
Dizziness12 (8.8)15 (11.1)0.550
Itching24 (17.6)29 (21.5)0.447
Headache20 (14.7)16 (11.9)0.592
Cough8 (5.9)9 (6.7)0.808
Serious adverse event0 (0)0 (0)
Discontinuation due to adverse event2 (1.4)1 (0.7)1.000
Death0 (0)0 (0)

Values in parentheses are percentages unless indicated otherwise.